Disaggregated Revenues

3 Months Ended

Mar. 31, 2022

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):

	Three Months ended March 31,
	2022		2021
	(unaudited)
Net product sales
Trokendi XR	$	62,832	$	71,819
Oxtellar XR	27,521		27,370
GOCOVRI	22,601		—
APOKYN	18,448		21,730
Qelbree	8,283		—
Other(1)	7,779		7,462
Total net product sales	$	147,464	$	128,381
Royalty revenues	5,042		2,551
Total revenues	$	152,506	$	130,932

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and OSMOLEX ER.

Trokendi XR accounted for 43% and 56% of the Company’s total net product sales for the three months ended March 31, 2022 and 2021, respectively.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% and 25% of our total net product sales and collectively accounted for more than 75% and 85% of our total net product sales in 2022 and 2021, respectively.

The Company recognized noncash royalty revenue of $2.2 million for both the three months ended March 31, 2022 and 2021. Refer to Note 16, Commitments and Contingencies.